Mekinist and Tafinlar

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Although this combination is used therapeutically and recommended for certain indications (e.g., melanoma, anaplastic thyroid cancer, non-small cell lung cancer), concomitant use of dabrafenib and trametinib may be associated with increased risk of severe and possibly life-threatening adverse events. These include skin toxicities (e.g., Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms), intracranial and gastrointestinal hemorrhage, venous thromboembolism, and serious febrile events. In an open label study patients with metastatic melanoma with BRAF V600 mutations (n=247) were treated with dabrafenib alone or dabrafenib and trametinib. Serious pyrexia with severe chills or hypotension or that required hospitalization occurred in 19 to 25% of patients treated with the combination as compared to 2% of patients in the monotherapy group. MANAGEMENT: The manufacturer's product labeling should be consulted for recommendations on dosage adjustments or discontinuation in the event of severe toxicities. Patients should be instructed to contact their doctor if they experience unusual bleeding or bruising or severe weakness; fever; red, purple or intolerable rash; shortness of breath, chest pain, or arm or leg swelling. References "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC. "Product Information. Mekinist (trametinib)." GlaxoSmithKline, Research Triangle Park, NC. Flaherty; Infante; Daud; Gonzalez; Kefford; Sosman; Hamid; Schuchter; Cebon; Ibrahim; Kudchadkar; Burris Nag "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations." NEJM 367:1694-1703 (2012): 5

MONITOR: Although this combination is used therapeutically and recommended for certain indications (e.g., melanoma, anaplastic thyroid cancer, non-small cell lung cancer), concomitant use of dabrafenib and trametinib may be associated with increased risk of severe and possibly life-threatening adverse events. These include skin toxicities (e.g., Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms), intracranial and gastrointestinal hemorrhage, venous thromboembolism, and serious febrile events. In an open label study patients with metastatic melanoma with BRAF V600 mutations (n=247) were treated with dabrafenib alone or dabrafenib and trametinib. Serious pyrexia with severe chills or hypotension or that required hospitalization occurred in 19 to 25% of patients treated with the combination as compared to 2% of patients in the monotherapy group.

MANAGEMENT: The manufacturer's product labeling should be consulted for recommendations on dosage adjustments or discontinuation in the event of severe toxicities. Patients should be instructed to contact their doctor if they experience unusual bleeding or bruising or severe weakness; fever; red, purple or intolerable rash; shortness of breath, chest pain, or arm or leg swelling.

Mekinist

Generic Name: trametinib

Brand name: Mekinist

Synonyms: n.a.

What is Mekinist?

Tafinlar

Generic Name: dabrafenib

Brand name: Tafinlar

Synonyms: n.a.

What is Tafinlar?